Last €16.67 EUR
Change Today -0.035 / -0.21%
Volume 0.0
AB3A On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 2:08 AM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

sarepta therapeutics inc (AB3A) Snapshot

Open
€16.66
Previous Close
€16.70
Day High
€16.97
Day Low
€16.66
52 Week High
10/7/13 - €40.75
52 Week Low
11/13/13 - €9.32
Market Cap
682.2M
Average Volume 10 Days
88.1
EPS TTM
--
Shares Outstanding
40.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SAREPTA THERAPEUTICS INC (AB3A)

sarepta therapeutics inc (AB3A) Details

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

146 Employees
Last Reported Date: 03/3/14
Founded in 1980

sarepta therapeutics inc (AB3A) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $580.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $457.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $377.7K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $376.9K
Senior Vice President of Technical Operations
Total Annual Compensation: $320.5K
Compensation as of Fiscal Year 2013.

sarepta therapeutics inc (AB3A) Key Developments

Sarepta Enters into Partnership with Flagship Biosciences Multi-Year, Multi-Product Partnership for the Development of Automated Quantitative Endpoint Measurements

Sarepta Therapeutics, Inc. and Flagship Biosciences LLC announced a multi-year, multi-product partnership for the development of automated quantitative endpoint measurements in muscular dystrophy to support the advancement of Sarepta's Duchenne muscular dystrophy (DMD) drug pipeline, including its lead candidate, eteplirsen. This newly established collaboration with Flagship demonstrates Sarepta's commitment to enhancing the objective measurement of dystrophin in tissue samples for its growing pipeline of RNA-based therapeutics to treat DMD. The agreement between the companies also further strengthens Flagship Biosciences' leadership role in diagnostic image analysis and digital pathology to support and optimize targeted drug development.

Sarepta Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revised Earnings Guidance for the Year 2014

Sarepta Therapeutics Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the second quarter, the company reported revenue from grants and research contracts was $2,583,000 compared with $2,951,000 for the same period in the last year. Operating loss was $30,271,000 compared with $17,087,000 for the same period in the last year. Net loss was $33,874,000 compared with $19,051,000 for the same period in the last year. Net loss per basic and diluted share was $0.85 compared with $0.60 for the same period in the last year. The increase in net loss is primarily due to an increase of $12.8 million in operating expenses, an increase of $1.8 million in loss on change in warrant valuation and a decrease of $0.4 million in contract revenue. Non-GAAP net loss was $24,501,000 compared with $14,579,000 for the same period in the last year. Non-GAAP net loss per basic and diluted share was $0.61 compared with $0.46 for the same period in the last year. The incremental loss of $9.9 million was primarily the result of increased research and development and general and administrative expenses as a result of corporate growth. Revenue decrease was primarily due to decreases in revenue from the company's government contracts. For the six months, the company reported revenue from grants and research contracts was $8,671,000 compared with $7,425,000 for the same period in the last year. Operating loss was $55,392,000 compared with $32,502,000 for the same period in the last year. Net loss was $62,147,000 compared with $61,135,000 for the same period in the last year. Net loss per basic and diluted share was $1.60 compared with $1.92 for the same period in the last year. Non-GAAP net loss was $45,172,000 compared with $27,624,000 for the same period in the last year. Non-GAAP net loss per basic and diluted share was $1.16 compared with $0.87 for the same period in the last year. The company now expects that non-GAAP loss from operations will range from $135 million to $145 million, as compared with its previous guidance of $110 to $120 million. In addition, the company is anticipating capital investments of approximately $25 million for the remainder of 2014 in connection with its manufacturing facility in Andover and 2015 inventory commitments. The company is not able to provide a reconciliation of this non-GAAP guidance to its relevant GAAP measure because full year loss from operations could include incremental stock compensation expense related to the achievement of certain criteria for performance awards.

Sarepta Therapeutics, Inc. Announces Executive Changes

Sarepta Therapeutics, Inc. John Hodgman, a member of Sarepta's board of directors, has been named interim chairman, effective July 30, 2014. William Goolsbee, chairman of the company's board of directors, has resigned as chairman and will continue to serve on the Sarepta board as an independent director. The company's board of directors announced that it fully supports Sarepta president and chief executive officer Chris Garabedian to lead the company as it advances its lead program eteplirsen for Duchenne muscular dystrophy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB3A:GR €16.67 EUR -0.035

AB3A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,567 GBp +87.50
Baxter International Inc $74.98 USD +0.07
Gilead Sciences Inc $107.56 USD +0.05
Hemispherx Biopharma Inc $0.27 USD +0.0007
SciClone Pharmaceuticals Inc $6.86 USD +0.23
View Industry Companies
 

Industry Analysis

AB3A

Industry Average

Valuation AB3A Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 57.0x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit www.sareptatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.